SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+33.62%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.69B
AUM Growth
+$1.69B
(-5.1%)
Cap. Flow
-$377M
Cap. Flow
% of AUM
-22.25%
Top 10 Holdings %
Top 10 Hldgs %
52.96%
Holding
89
New
27
Increased
18
Reduced
14
Closed
20
Top Buys
| 1 |
Novo Nordisk
NVO
|
$78.6M |
| 2 |
Incyte
INCY
|
$58.7M |
| 3 |
argenx
ARGX
|
$41.2M |
| 4 |
Idexx Laboratories
IDXX
|
$40.6M |
| 5 |
Insulet
PODD
|
$34.5M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$437M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$150M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$45.9M |
| 4 |
Eli Lilly
LLY
|
$37.6M |
| 5 |
Cytokinetics
CYTK
|
$34.6M |
Sector Composition
| 1 | Healthcare | 99.18% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Teleflex
TFX
$5.57B
| $2.75M | 0.15% |
+12,142
| New | +$2.75M |
|
52
Cooper Companies
COO
$13.3B
| $2.15M | 0.12% |
21,236
+5,236
| +33% | +$531K |
|
53
Inspire Medical Systems
INSP
$2.53B
| $1.74M | 0.1% |
+8,099
| New | +$1.74M |
|
54
LivaNova
LIVN
$3.09B
| $1.14M | 0.06% |
+20,456
| New | +$1.14M |
|
|
NCNA
55
NuCana
NCNA
$5.8M
| $884K | 0.05% |
680
-257
| -27% | -$334K |
|
56
Amylyx Pharmaceuticals
AMLX
$877M
| $871K | 0.05% |
+306,729
| New | +$871K |
|
57
Baxter International
BAX
$12.1B
| $855K | 0.05% |
+20,000
| New | +$855K |
|
|
IMTXW
58
DELISTED
Immatics N.V. Warrants
IMTXW
| $853K | 0.05% |
316,349
-2,023
| -0.6% | -$5.46K |
|
59
PDS Biotechnology
PDSB
$60.6M
| $565K | 0.03% |
142,635
| – | – |
|
|
IMA
60
ImageneBio, Inc. Common Stock
IMA
$153M
| $543K | 0.03% |
31,885
+1,595
| +5% | +$27.2K |
|
61
Perspective Therapeutics
CATX
$251M
| $512K | 0.03% |
+43,011
| New | +$512K |
|
|
NARI
62
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $490K | 0.03% |
+10,216
| New | +$490K |
|
63
Disc Medicine
IRON
$2.14B
| $384K | 0.02% |
+6,173
| New | +$384K |
|
64
Structure Therapeutics
GPCR
$1.14B
| $374K | 0.02% |
8,733
-166,105
| -95% | -$7.12M |
|
65
Kyverna Therapeutics
KYTX
$161M
| $248K | 0.01% |
+10,000
| New | +$248K |
|
66
Mirum Pharmaceuticals
MIRM
$3.75B
| $75.7K | ﹤0.01% |
3,012
-349,385
| -99% | -$8.78M |
|
67
Insmed
INSM
$30.3B
| – | – |
0
| – | – |
|
|
AGEN
68
Agenus
AGEN
$136M
| – | – |
-782,812
| Closed | -$13M |
|
|
69
Cytokinetics
CYTK
$5.98B
| – | – |
-414,207
| Closed | -$34.6M |
|
70
DexCom
DXCM
$30.9B
| – | – |
-20,000
| Closed | -$2.48M |
|
71
Fulcrum Therapeutics
FULC
$353M
| – | – |
-28,600
| Closed | -$193K |
|
72
Geron
GERN
$893M
| – | – |
-8,814,497
| Closed | -$18.6M |
|
73
Immunovant
IMVT
$2.91B
| – | – |
-222,553
| Closed | -$9.38M |
|
74
Ironwood Pharmaceuticals
IRWD
$201M
| – | – |
-331,099
| Closed | -$3.79M |
|
75
Kenvue
KVUE
$39.2B
| – | – |
-1,206,939
| Closed | -$26M |
|